• Immunovia plans to issue up to 1,057,047,973 free warrants of series TO 4 through a rights issue, subject to shareholder approval October 29, 2026.
• Each SEK 0.06 unit comprises two shares and one warrant; subscriptions run November 9–23, 2026.
• Each warrant entitles holders to subscribe for one share at SEK 0.03 during April 19–May 3, 2027.
• Full warrant exercise would raise approximately SEK 31.7 million before costs, supplementing approximately SEK 63.4 million from the rights issue.
• Total dilution would reach approximately 82.5% if the rights issue is fully subscribed and all warrants are exercised.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovia AB published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.